NASDAQ:HBIO

Harvard Bioscience - HBIO Stock Forecast, Price & News

$2.38

-0.02 (-0.83%)

(As of 09/27/2022 12:54 PM ET)

Add

Compare

Today's Range: $2.33
▼
$2.49
50-Day Range: $2.40
▼
$3.81
52-Week Range: $2.39
▼
$8.23

Volume: 3,183 shs
Average Volume: 91,343 shs
Market Capitalization: $99.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Harvard Bioscience MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 194.1% Upside
$7.00 Price Target
Short Interest: Healthy
0.75% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.62
Upright™ Environmental Score
News Sentiment: 0.07
Based on 9 Articles This Week
Insider Trading: Acquiring Shares
$234,345 Bought Last Quarter
Proj. Earnings Growth: 360.00%
From $0.05 to $0.23 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Computer And Technology Sector

117th out of 636 stocks

Analytical Instruments Industry

3rd out of 28 stocks

3.5

Analyst's Opinion

Consensus Rating
Harvard Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Harvard Bioscience has a forecasted upside of 194.1% from its current price of $2.38.
Amount of Analyst Coverage
Harvard Bioscience has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.75% of the float of Harvard Bioscience has been sold short.
Short Interest Ratio / Days to Cover
Harvard Bioscience has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Harvard Bioscience has recently decreased by 5.79%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Harvard Bioscience does not currently pay a dividend.
Dividend Growth
Harvard Bioscience does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Harvard Bioscience has received a 72.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Basic medical research services" and "Medical laboratory equipment" products. See details.
Environmental Sustainability
The Environmental Impact score for Harvard Bioscience is -0.62.

1.2

News and Social Media Coverage

News Sentiment
Harvard Bioscience has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Computer and Technology companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Harvard Bioscience this week, compared to 11 articles on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Harvard Bioscience insiders have bought more of their company's stock than they have sold. Specifically, they have bought $234,345.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 6.20% of the stock of Harvard Bioscience is held by insiders.
Percentage Held by Institutions
71.44% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Harvard Bioscience are expected to grow by 360.00% in the coming year, from $0.05 to $0.23 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Harvard Bioscience is -26.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Harvard Bioscience is -26.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Harvard Bioscience has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Harvard Bioscience (NASDAQ:HBIO) Stock

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

HBIO Stock News Headlines

September 26, 2022 | msn.com

This boy from Patna has become president of student union at Harvard

September 26, 2022 | nasdaq.com

Further weakness as Harvard Bioscience (NASDAQ:HBIO) drops 13% this week, taking one-year losses to 66%

September 26, 2022 | finance.yahoo.com

When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Breakeven?

September 24, 2022 | msn.com

Harvard football gets out to fast start, holds off Brown’s fourth-quarter rally

September 22, 2022 | msn.com

Zuckerberg, Chan want new Harvard institute to answer questions about the brain, AI

September 22, 2022 | msn.com

Odor of smoke at Harvard station causes commuter headache

September 22, 2022 | seekingalpha.com

HBIO Harvard Bioscience, Inc.

September 22, 2022 | msn.com

Mark Zuckerberg is ‘derailing’ Facebook, says Harvard expert—here's how he can get ‘back on track'

September 19, 2022 | msn.com

Elise Stefanik claims Harvard discussed 'taking' her degree along with Ted Cruz's

September 19, 2022 | msn.com

Harvard-backed company makes an EV battery that fully charges in three minutes

September 18, 2022 | msn.com

Here are the best foods to feed kids, according to a Harvard brain expert

September 18, 2022 | msn.com

Here are the best foods to feed kids, according to a Harvard brain expert

September 18, 2022 | msn.com

Harvard Expert Says Zuckerberg Is Derailing Facebook: 'I Think The Wealth Went To His Head'

September 17, 2022 | msn.com

Dean’s long TD pass in OT gets Harvard past Merrimack 28-21

September 17, 2022 | msn.com

Harvard football holds off Merrimack in overtime

September 16, 2022 | msn.com

Trump Allies to Face 'Avalanche' of Indictments in 2023: Harvard Law Expert

September 16, 2022 | msn.com

From Lanai to Harvard and back again: How one woman found her calling at home

September 15, 2022 | barrons.com

Harvard Alumni Account for 5% of the World’s Ultra-High-Net-Worth Population

September 15, 2022 | msn.com

Lanai’s only Harvard grad finds calling to return home to give back to her island

September 15, 2022 | msn.com

Billionaire Jim Koch says his Harvard MBA didn't prepare him to launch Sam Adams: Experience can 'be a lot more important than intelligence'

September 15, 2022 | msn.com

Harvard nutritionist: This is the No. 1 vitamin to keep your brain sharp

September 15, 2022 | msn.com

Harvard-backed startup develops game-changing EV battery that charges in 3 minutes, lasts 20 years

September 14, 2022 | msn.com

Harvard students could be punished for not using preferred pronouns: Report

September 13, 2022 | bizjournals.com

'Generation Q': Harvard, AWS form quantum networking alliance

September 12, 2022 | msn.com

Former CNN host Brian Stelter lands Harvard media fellowship

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

HBIO Company Calendar

Last Earnings: 8/03/2022
Today: 9/27/2022
Next Earnings (Estimated): 11/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Analytical instruments
Sub-Industry: Life Sciences Tools & Services
Sector: Computer and Technology
Current Symbol: NASDAQ:HBIO
CUSIP: 41690610
CIK: 1123494
Web: www.harvardbioscience.com
Phone: (508) 893-8999
Fax: 508-429-5732
Employees: 475
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.00
High Stock Price Forecast: $7.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +194.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 47.60
P/E Growth: N/A
Net Income: $-290,000.00
Net Margins: -3.03%
Pretax Margin: -2.01%
Return on Equity: 7.74%
Return on Assets: 3.86%

Debt

Debt-to-Equity Ratio: 0.59
Current Ratio: 2.42
Quick Ratio: 1.16

Sales & Book Value

Annual Sales: $118.90 million
Price / Sales: 0.83
Cash Flow: $0.35 per share
Price / Cash Flow: 6.72
Book Value: $2.04 per share
Price / Book: 1.17

Miscellaneous

Outstanding Shares: 41,640,000
Free Float: 39,056,000
Market Cap: $99.10 million
Optionable: Optionable
Beta: 1.73

Key Executives

Mr. James W. Green (Age 64)
Pres, CEO & Chairman
Comp: $1.02M

Mr. Michael A. Rossi (Age 48)
Chief Financial Officer
Comp: $478.75k

Mr. Kenneth Fletcher Olson (Age 60)
Exec. Officer
Comp: $414.31k

Mr. David Balcom
Sr. VP of Operations

Ms. Kara Weiner
Sr. VP of Marketing & Product Management

David Sirois
Director of Corp. Accounting & SEC Reporting

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HBIO Stock - Frequently Asked Questions

Should I buy or sell Harvard Bioscience stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" HBIO shares.
View HBIO analyst ratings or view top-rated stocks.
What is Harvard Bioscience's stock price forecast for 2022?: 1 Wall Street research analysts have issued 12 month price targets for Harvard Bioscience's stock. Their HBIO share price forecasts range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 194.1% from the stock's current price.
View analysts price targets for HBIO or view top-rated stocks among Wall Street analysts.
How have HBIO shares performed in 2022?: Harvard Bioscience's stock was trading at $7.05 at the beginning of the year. Since then, HBIO shares have decreased by 66.2% and is now trading at $2.38.
View the best growth stocks for 2022 here.
When is Harvard Bioscience's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our HBIO earnings forecast.
How were Harvard Bioscience's earnings last quarter?: Harvard Bioscience, Inc. (NASDAQ:HBIO) announced its earnings results on Wednesday, August, 3rd. The medical instruments supplier reported $0.02 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.01. The medical instruments supplier had revenue of $29.21 million for the quarter, compared to analyst estimates of $30.10 million. Harvard Bioscience had a negative net margin of 3.03% and a positive trailing twelve-month return on equity of 7.74%.
What other stocks do shareholders of Harvard Bioscience own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

What is Harvard Bioscience's stock symbol?: Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."
Who are Harvard Bioscience's major shareholders?: Harvard Bioscience's stock is owned by a number of institutional and retail investors. Top institutional investors include Royce & Associates LP (3.93%), B. Riley Asset Management LLC (3.71%), AMH Equity Ltd (3.03%), Renaissance Technologies LLC (2.40%), Monarch Partners Asset Management LLC (1.94%) and Meros Investment Management LP (1.49%). Insiders that own company stock include Alan I Edrick, Bertrand Loy, James W Green, James W Green and Value Fund Lp Palogic.
View institutional ownership trends.
How do I buy shares of Harvard Bioscience?: Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Harvard Bioscience's stock price today?: One share of HBIO stock can currently be purchased for approximately $2.38.
How much money does Harvard Bioscience make?: Harvard Bioscience (NASDAQ:HBIO) has a market capitalization of $99.10 million and generates $118.90 million in revenue each year. The medical instruments supplier earns $-290,000.00 in net income (profit) each year or ($0.09) on an earnings per share basis.
How many employees does Harvard Bioscience have?: The company employs 475 workers across the globe.
How can I contact Harvard Bioscience?: Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The official website for the company is www.harvardbioscience.com. The medical instruments supplier can be reached via phone at (508) 893-8999, via email at info@harvardbioscience.com, or via fax at 508-429-5732.

This page (NASDAQ:HBIO) was last updated on 9/27/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Harvard Bioscience - HBIO Stock Forecast, Price & News

Harvard Bioscience MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Harvard Bioscience (NASDAQ:HBIO) Stock

HBIO Stock News Headlines

HBIO Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

HBIO Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™